STOK logo

STOK
Stoke Therapeutics Inc

1,009
Mkt Cap
$1.89B
Volume
563,538.00
52W High
$40.22
52W Low
$5.35
PE Ratio
-215.42
STOK Fundamentals
Price
$32.74
Prev Close
$31.99
Open
$31.04
50D MA
$33.09
Beta
1.31
Avg. Volume
986,806.54
EPS (Annual)
-$0.1163
P/B
5.35
Rev/Employee
$1.08M
$1,598.60
Loading...
Loading...
News
all
press releases
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, nine have...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Key PointsThe chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026...
Nasdaq News: Markets·6d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) Sees Strong Trading Volume - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.4% in the fourth quarter, according to its most recent disclosure with the...
MarketBeat·8d ago
News Placeholder
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
Key PointsThe chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026...
Nasdaq News: Markets·9d ago
News Placeholder
FY2030 Earnings Estimate for STOK Issued By HC Wainwright
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Stoke Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst A. Ghosh anticipates that the company will earn $4.03 per share for the year. H...
MarketBeat·11d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered Stoke Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock
Canaccord Genuity Group boosted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·13d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,461 Shares
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,461 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average...
MarketBeat·13d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $60,517.54 in Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Jason Hoitt sold 1,931 shares of the business's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $60,517.54. Following the sale, the insider owned 10,276 shares of...
MarketBeat·14d ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.